Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.

ANA MARTINEZ is the Research and Development Director for NeuroPharma. She has been and still is an active researcher in the design and synthesis of GSK-3 inhibitors.

ANA CASTRO is the Medicinal Chemistry Director of NeuroPharma. She was formerly a tenured scientist at the Medicinal Chemistry Institute.

MIGUEL MEDINA is the Drug Discovery Director at NeuroPharma. He was formerly an instructor at the Brigham and Women's Hospital and the Harvard Medical School.